Level C· Early human research exploring benefitsCohort StudyPubMedOpen access

Long-Term Outcome of Fat Grafting to Treat Facial Systemic Sclerosis: A Prospective Cohort Study.

Almadori A., Griffin M., Hyun J., Hansen E., Denton CP., Butler PEM.

Cohort Study with a reported sample of 93 on Face & Skin, Systemic / IV, published in Plast Reconstr Surg (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Cohort Study
Journal
Plast Reconstr Surg (2025)
Country
United States
Reported sample size
93
Source database
PubMed
PMID
40137689
PMCID
PMC12456191
DOI
10.1097/PRS.0000000000012111
Citations
2

Abstract (original English)

Systemic sclerosis (SSc) is characterized by subcutaneous tissue loss and dermal fibrosis, with limited facial movement and mouth opening. Fat grafting is a minimally invasive technique used to restore facial volume and improve skin fibrosis. A cohort of 93 patients were assessed using 3-dimensional imaging before and after fat grafting. Secondary outcomes included physician-based assessment; mouth function (using the Mouth Handicap in Systemic Sclerosis Scale), psychological status, quality of life (using the Derriford Appearance Scale, Hospital Anxiety and Depression Scale, visual analog scale, and Brief Fear of Negative Evaluation Scale); and patient satisfaction. After an average of 2.96 ± 2.2 sessions of fat grafting, with an injection volume of 11.9 ± 6 cc in each session, the overall retention rate was 53.1% ± 0.17% at an average follow-up of 3.11 ± 1.73 years. Patients undergoing 5 or more interventions presented a higher retention rate (73.1% ± 0.08%) than those receiving 1 or 2 treatments (45.2% ± 0.09% and 50.5% ± 0.15%, respectively) ( P < 0.05). Significant improvements were found in mouth function ( P < 0.0001) and quality of life ( P < 0.0001). Facial fat grafting is an effective technique for restoring facial volume and improving oral function and quality of life in patients with scleroderma. This study presents the largest number of patients published to date w

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansFemaleScleroderma, SystemicMiddle AgedProspective StudiesMaleTreatment OutcomeAdipose TissueQuality of LifeAdult

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research